Inhibikase Therapeutics (IKT) Return on Sales (2020 - 2023)
Historic Return on Sales for Inhibikase Therapeutics (IKT) over the last 5 years, with Q3 2024 value amounting to 20063937.0%.
- Inhibikase Therapeutics' Return on Sales fell 200638770700.0% to 20063937.0% in Q3 2024 from the same period last year, while for Sep 2024 it was 20063937.0%, marking a year-over-year decrease of 200638752200.0%. This contributed to the annual value of 77.12% for FY2023, which is 697400.0% up from last year.
- As of Q3 2024, Inhibikase Therapeutics' Return on Sales stood at 20063937.0%, which was down 200638770700.0% from 238.85% recorded in Q2 2024.
- In the past 5 years, Inhibikase Therapeutics' Return on Sales ranged from a high of 1.87% in Q1 2021 and a low of 20063937.0% during Q3 2024
- Over the past 5 years, Inhibikase Therapeutics' median Return on Sales value was 68.2% (recorded in 2022), while the average stood at 1288008.65%.
- As far as peak fluctuations go, Inhibikase Therapeutics' Return on Sales surged by 25252300bps in 2022, and later crashed by 2000000000bps in 2024.
- Inhibikase Therapeutics' Return on Sales (Quarter) stood at 7.09% in 2020, then crashed by -36487bps to 2593.43% in 2021, then skyrocketed by 97bps to 68.2% in 2022, then plummeted by -6457080bps to 4403566.0% in 2023, then tumbled by -356bps to 20063937.0% in 2024.
- Its Return on Sales was 20063937.0% in Q3 2024, compared to 238.85% in Q2 2024 and 102.85% in Q1 2024.